Stories - Corcept Therapeutics

Stories and perspectives.

Featured
Stories

We are Corcept.

Founding Corcept

All Stories

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes

Navigating Hypercortisolism: Deile’s Story

Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions

Press Release: Jun 24, 2024

Celebrating Dr. Neena Schwartz

Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)

Press Release: May 28, 2024

What is Hypercortisolism?

Featured Content:

Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian Cancer

Publication: March 18, 2024

Cushing’s Syndrome: A Patient Advocate Perspective